SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SPARC reports net loss of Rs 36.41 core in Q1

01 Aug 2016 Evaluate

Sun Pharma Advanced Research Company (SPARC) reported results for first quarter ended June 30, 2016.

The company has reported a net loss at Rs 36.41 crore for the quarter ended June 30, 2016 as compared to net loss of Rs 1.65 crore for the same quarter in the previous year. The company’s total income decreased by 43.94% to Rs 24.47 crore for the quarter under review from Rs 43.65 crore for the corresponding quarter of the previous year.

Sun Pharma Advanced Research Company is an international pharmaceutical company engaged in research and development of drugs and delivery systems.

Sun Pharma Adv. Res Share Price

147.90 -4.25 (-2.79%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 435.70
Indegene 486.80
CMS Info Systems 318.00
JITF Infralogistics 338.00
Sagility 42.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×